Danaher DHR Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Sales by Business | ||||||
| Biotechnology | $1.8B-11.6% | $2.03B+13.1% | $1.8B-2.8% | $1.85B+14.8% | $1.61B-13.8% | |
| Diagnostics | $2.42B-11.1% | $2.72B+10.4% | $2.46B+6.7% | $2.31B-5.7% | $2.45B-7.1% | |
| Life Sciences | $1.74B-16.7% | $2.09B+16.4% | $1.79B+0.8% | $1.78B+5.8% | $1.68B-17.3% | |
| Segment Reporting, Other Segment Item, Amount by Business | ||||||
| Biotechnology | $989M-19.2% | $1.22B+12.2% | $1.09B+3.6% | $1.05B+14.0% | $924M-16.8% | |
| Diagnostics | $1.59B-14.1% | $1.85B+13.5% | $1.63B+1.7% | $1.61B+1.5% | $1.58B-13.1% | |
| Life Sciences | $1.31B-14.6% | $1.54B+12.2% | $1.37B-1.4% | $1.39B+8.1% | $1.29B-12.2% | |
| Operating Income (Loss) by Business | ||||||
| Biotechnology | $534M-1.1% | $540M+53.4% | $352M-33.7% | $531M+20.4% | $441M-13.2% | |
| Diagnostics | $674M-5.5% | $713M+7.2% | $665M+20.0% | $554M-22.8% | $718M+15.1% | |
| Life Sciences | $225M-33.0% | $336M+51.4% | $222M+193% | -$239M-219% | $201M-46.5% | |
| Identifiable assets by Business | ||||||
| Biotechnology | $36.7B-1.7% | $37.34B+0.1% | $37.3B-0.7% | $37.56B+4.0% | $36.12B+4.4% | |
| Diagnostics | $14.66B-0.6% | $14.75B— | —— | —— | —— | |
| Life Sciences | $22.87B-1.0% | $23.11B— | —— | —— | —— | |
| Depreciation by Business | ||||||
| Biotechnology | $40M+2.6% | $39M+2.6% | $38M0.0% | $38M+11.8% | $34M-10.5% | |
| Diagnostics | $102M-3.8% | $106M+5.0% | $101M+1.0% | $100M0.0% | $100M-2.0% | |
| Life Sciences | $48M0.0% | $48M+2.1% | $47M+4.4% | $45M0.0% | $45M+2.3% | |
| Capital expenditures, gross by Business | ||||||
| Biotechnology | $64M-44.3% | $115M+22.3% | $94M+17.5% | $80M-1.2% | $81M-30.8% | |
| Diagnostics | $144M-26.2% | $195M+24.2% | $157M+25.6% | $125M+8.7% | $115M-31.5% | |
| Life Sciences | $27M-52.6% | $57M+42.5% | $40M-2.4% | $41M-14.6% | $48M-79.0% | |
| Intangible Amortization by Business | ||||||
| Biotechnology | $234M+1.7% | $230M-0.4% | $231M+1.3% | $228M+7.0% | $213M0.0% | |
| Diagnostics | $48M+2.1% | $47M-2.1% | $48M0.0% | $48M0.0% | $48M+2.1% | |
| Life Sciences | $152M+0.7% | $151M-1.9% | $154M+2.7% | $150M+0.7% | $149M+0.7% | |
| Goodwill by Business | ||||||
| Biotechnology | $23B-1.3% | $23.31B+0.7% | $23.15B0.0% | $23.14B+3.7% | $22.32B+4.1% | |
| Diagnostics | $6.96B-0.3% | $6.98B+0.2% | $6.97B-0.1% | $6.97B+2.0% | $6.84B+1.2% | |
| Life Sciences | $12.81B-0.4% | $12.86B+0.1% | $12.84B-0.3% | $12.88B+3.0% | $12.51B+1.6% | |
| Sales by Product | ||||||
| Nonrecurring revenue | $920M-39.2% | $1.51B+46.1% | $1.04B+7.2% | $966M+4.4% | $925M-35.5% | |
| Recurring revenue | $5.03B-5.5% | $5.32B+6.1% | $5.02B+0.9% | $4.97B+3.2% | $4.82B-5.7% | |
| Sales by Geography | ||||||
| High-growth markets | $1.62B-19.9% | $2.03B+15.1% | $1.76B+3.8% | $1.7B+10.4% | $1.54B-19.7% | |
| North America | $2.48B-10.1% | $2.76B+6.8% | $2.58B+5.8% | $2.44B-5.6% | $2.58B-6.9% | |
| Other developed markets | $284M-22.0% | $364M+15.2% | $316M+7.5% | $294M+5.8% | $278M-22.6% | |
| Western Europe | $1.57B-7.5% | $1.69B+21.1% | $1.4B-7.4% | $1.51B+12.1% | $1.34B-9.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Danaher break its business down?
- Danaher (DHR) reports sales by business across 3 parts — Biotechnology, Diagnostics and Life Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Danaher's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Danaher's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
